Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) and Quince Therapeutics (NASDAQ:QNCX) Head-To-Head Survey

Quince Therapeutics (NASDAQ:QNCX) and Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Institutional & Insider Ownership

30.8% of Quince Therapeutics shares are held by institutional investors. 16.8% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Quince Therapeutics and Quantum Genomics Société Anonyme, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	0	0	4	2	3.33
Quantum Genomics Société Anonyme	0	0	0	0	0.00

Quince Therapeutics currently has a consensus price target of $9.50, suggesting a potential upside of 555.17%. Given Quince Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Quince Therapeutics is more favorable than Quantum Genomics Société Anonyme.

Profitability

This table compares Quince Therapeutics and Quantum Genomics Société Anonyme’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-53.27%	-22.73%
Quantum Genomics Société Anonyme	N/A	N/A	N/A

Volatility & Risk

Quince Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Quantum Genomics Société Anonyme has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500.

Earnings & Valuation

This table compares Quince Therapeutics and Quantum Genomics Société Anonyme”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$31.39 million	($1.24)	-1.17
Quantum Genomics Société Anonyme	N/A	N/A	N/A	N/A	N/A

Summary

Quince Therapeutics beats Quantum Genomics Société Anonyme on 7 of the 9 factors compared between the two stocks.

About Quince Therapeutics

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

About Quantum Genomics Société Anonyme

Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.